Synthetic Blood Intl. Gets Five New Patents

March 2000
Worldwide Biotech;Mar2000, Vol. 12 Issue 3, p1
Trade Publication
Reports on the number of patents issued by Synthetic Blood International Inc. in the United States and Australia as of March 2000.


Related Articles

  • New blood for OC biotech sector.  // Orange County Business Journal;06/01/98, Vol. 21 Issue 22, p38 

    Reports on Kettering, Ohio-based Synthetic Blood International's plan to open an office in Orange County, California.

  • Oxycyte on track as oxygen carrier, not blood substitute.  // Medical Technology & Devices Week;5/12/2008, Vol. 6 Issue 19, p2 

    This article reports on the reiteration by Synthetic Blood International that its Oxycyte is not a synthetic blood and is not hemoglobin-based. The move by the company to make such reiteration is in reaction to the news that blood substitutes have led to a 30% increase in the risk of death and...

  • Synthetic Blood now Oxygen Biotherapeutics.  // Biomedical Business & Technology;Aug2008, Vol. 31 Issue 8, p27 

    The article announces the change in name of Synthetic Blood International to Oxygen Biotherapeutics along with the company's new trading symbol on the Over-the-Counter Bulletin Board to OXBO. According to chief executive officer (CEO) Chris Stern, the new name better reflects the broader scope...

  • SBI inks license accord with VCU Tech Transfer on patents.  // Medical Device Daily;5/27/2008, Vol. 12 Issue 101, p4 

    The article announces that the Synthetic Blood International (SBI) and the Virginia Commonwealth University's Tech Transfer unit, of Richmond, Virginia have signed a license agreement that lets the company use certain VCU discoveries related to non-pulmonary oxygenation, enhanced oxygen...

  • Synthetic Blood proposes name change.  // Medical Device Daily;4/29/2008, Vol. 12 Issue 83, p5 

    The article reports that Synthetic Blood International will propose a name change to its shareholders. The new name would be Oxygen Therapeutics. In addition, shareholders will also be asked to approve a change in the company's state of incorporation, as well as an increase in the number of...

  • Synthetic Blood gets promising early results with Oxycyte trial. Pedersen, Amanda // Medical Device Daily;5/17/2007, Vol. 11 Issue 95, p1 

    The article reports on the results of the Phase IIa study done by Synthetic Blood International on Oxycyte in patients with traumatic brain injury, in May 2007. The research found the primary endpoint of increasing oxygen tension levels of patients in comparison with the baseline. It shows that...

  • Synthetic Blood to lease Richmond office.  // Medical Device Daily;5/8/2008, Vol. 12 Issue 90, p5 

    The article reports that Synthetic Blood International of Costa Mesa, California has signed an agreement to lease space for a research office in the Virginia BioTechnology Research Park in Richmond, Virginia. The space will be used to coordinate research between the company and sponsored...

  • MED-TECH NEWS AND NOTES.  // Medical Device Daily;7/8/2008, Vol. 12 Issue 130, p4 

    This section offers news briefs on medical technology. Boston, Massachusetts-based pSivida has announced that the symbol for its common stock has returned to PSDV. The Online Healthcare Marketplace, a new platform that lets health plans provide online care services to consumers and physicians,...

  • Oxycyte on track as oxygen carrier, not blood substitute. Yoffee, Lynn // Medical Device Daily;5/5/2008, Vol. 12 Issue 87, p1 

    This article deals with the clarification issued by Synthetic Blood International (SBI) regarding its flagship product Oxycyte. According to SBI, Oxycyte is not a synthetic blood and is not hemoglobin-based. Particular focus is given to the target application of Oxycyte, which is being developed...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics